This presentation and the discussions during this conference call contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; regulatory discussions, submissions, filings, and approvals; the potential benefits, safety, and efficacy of our and our collaboration partners' products and in ...

Financial Performance - Fourth quarter 2024 total revenue was $2.5 billion, representing a 3% growth year-over-year; full year 2024 total revenue was $9.7 billion, a 2% decline year-over-year[1][5] - GAAP diluted EPS for Q4 2024 was $1.83, a 7% increase year-over-year; full year 2024 GAAP diluted EPS was $11.18, a 40% increase year-over-year[1][5] - Non-GAAP diluted EPS for Q4 2024 was $3.44, a 17% increase year-over-year; full year 2024 Non-GAAP diluted EPS was $16.47, a 12% increase year-over-year[1][5] - Total revenue for the twelve months ended December 31, 2024, was $7,213.5 million, compared to $7,246.7 million in 2023, indicating a decrease of approximately 0.5%[43] - Non-GAAP net income attributable to Biogen Inc. for Q4 2024 was $502.4 million, up from $430.3 million in Q4 2023, representing a 16.8% increase[49] - Net income attributable to Biogen Inc. for the twelve months ended December 31, 2024, was $1,632.2 million, compared to $1,161.1 million for 2023, reflecting a significant increase of 40.5%[33] Revenue Breakdown - LEQEMBI generated approximately $87 million in global in-market sales during Q4 2024, with U.S. sales around $50 million[4][5] - SKYCLARYS revenue for Q4 2024 was approximately $102 million, with U.S. revenue impacted by channel inventory and Medicare discount dynamics[4][5] - Revenue from Multiple Sclerosis (MS) products totaled $4,349.8 million for the twelve months ended December 31, 2024, down from $4,661.9 million in 2023, reflecting a decline of about 6.7%[41] - The revenue from SPINRAZA for the twelve months ended December 31, 2024, was $1,573.2 million, compared to $1,741.2 million in 2023, a decrease of approximately 9.7%[41] - OCREVUS royalties for Q4 2024 were $353.7 million, up from $338.0 million in Q4 2023, representing an increase of about 4.9%[43] - TYSABRI revenue for the twelve months ended December 31, 2024, was $1,715.0 million, compared to $1,876.9 million in 2023, a decline of approximately 8.6%[41] - The total revenue from biosimilars for the twelve months ended December 31, 2024, was $793.1 million, compared to $770.0 million in 2023, showing an increase of about 3.0%[41] Cost and Expenses - Research and development expenses for the year were $2,041.8 million, down from $2,462.0 million in 2023, showing a decrease of 17.1%[33] - Total cost of sales (Non-GAAP) for Q4 2024 was $540.5 million, down from $586.8 million in Q4 2023, reflecting a decrease of 7.9%[46] - Research and development expenses (Non-GAAP) for Q4 2024 were $528.2 million, a slight decrease from $568.1 million in Q4 2023[46] - Total selling, general and administrative expenses (Non-GAAP) for Q4 2024 were $672.5 million, compared to $587.9 million in Q4 2023, an increase of 14.4%[46] Cash and Debt Position - As of December 31, 2024, Biogen had cash and cash equivalents totaling approximately $2.4 billion and total debt of approximately $6.3 billion, resulting in net debt of approximately $3.9 billion[19] - The company’s cash and cash equivalents rose to $2,375.0 million as of December 31, 2024, compared to $1,049.9 million a year earlier, indicating a substantial increase of 126.5%[35] Future Outlook - Full year 2025 financial guidance projects Non-GAAP diluted EPS between $15.25 and $16.25, with total revenue expected to decline by a mid-single digit percentage compared to 2024[3][14] - The company anticipates a multi-billion dollar potential from its late-stage pipeline, indicating strong future growth prospects[25] - Biogen aims to enhance its commercial portfolio for long-term sustainable growth, focusing on strategic elements and disciplined business development[25] - The company is actively pursuing new product launches, including LEQEMBI, which is expected to contribute significantly to future revenues[25] Product Development and Initiatives - Biogen initiated a second Phase 3 study for Dapirolizumab pegol in systemic lupus erythematosus, with positive results from the first Phase 3 study presented at a major conference[4][5] - In February 2025, Royalty Pharma plc agreed to provide up to $250 million in R&D funding for litifilimab, with potential future royalties based on net sales[20] - New product QALSODY became commercially available in the U.S. in Q2 2023 and is expected to contribute to future revenue growth as it becomes available in the E.U. in Q2 2024[38] Other Financial Metrics - Free cash flow for the twelve months ended December 31, 2024, was $2,721.8 million, significantly higher than $1,270.2 million for the same period in 2023[55] - The effective tax rate (Non-GAAP) for Q4 2024 was 12.2%, compared to 17.0% in Q4 2023[48] - The company reported a net cash provided by operating activities of $760.9 million for Q4 2024, a significant increase from $12.5 million in Q4 2023[55]

A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021.Biogen on Wednesday posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth. But the biotech company's guidance for the current year missed Wall Street's expectations. Biogen issued a full-year 2025 adjusted earnings outlook of $15.25 to $16.25 per share, which fell short of the ...

Biogen Inc. BIIB will release its fourth-quarter financial results, before the opening bell, on Wednesday, Feb. 12, 2025.Analysts expect the Cambridge, Massachusetts-based company to report quarterly earnings at $3.36 per share, up from $2.95 per share in the year-ago period. Biogen projects quarterly revenue of $2.42 billion, compared to $2.39 billion a year earlier, according to data from Benzinga Pro.Sage Therapeutics recently announced that its Board of Directors initiated a process to explore strategic ...

Core Viewpoint - Analysts project Biogen Inc. (BIIB) will report quarterly earnings of $3.45 per share, a 17% increase year over year, with revenues expected to reach $2.42 billion, reflecting a 1.3% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 0.7% over the past 30 days, indicating a collective reassessment by analysts [2]. - Revisions to earnings estimates are crucial for predicting investor actions, as empirical research shows a strong correlation between earnings estimate trends and short-term stock performance [3]. Revenue Projections - Analysts estimate that revenue from the product TYSABRI for Multiple Sclerosis (MS) will be $394.22 million, showing a year-over-year decline of 15.2% [5]. - Revenue from SPINRAZA for Rare Diseases is projected at $416.10 million, indicating a 0.9% increase year over year [5]. - Revenue from Anti-CD20 therapeutic programs is expected to be $442.52 million, reflecting a 1.5% increase year over year [6]. - Total net product revenue is estimated to be $1.81 billion, suggesting a year-over-year decline of 1% [6]. Specific Product Revenue Estimates - Revenue from TYSABRI in the United States is projected at $214.54 million, a decrease of 13.4% from the prior year [7]. - Revenue from TECFIDERA in the Rest of the World is expected to reach $181.80 million, indicating a 0.7% increase year over year [7]. - Revenue from TYSABRI in the Rest of the World is estimated at $177.74 million, reflecting an 18.1% decline year over year [8]. - Revenue from TECFIDERA in the United States is projected at $39.62 million, showing a significant decrease of 37.9% from the prior year [8]. - Revenue from SPINRAZA in the United States is expected to be $156.54 million, indicating a slight decline of 0.6% year over year [9]. - Revenue from Interferon for MS in the Rest of the World is estimated at $97.93 million, reflecting a 10.7% decline year over year [9]. - Revenue from Interferon for MS in the United States is projected at $140.99 million, indicating a 17.2% decline year over year [10]. - Revenue from SPINRAZA in the Rest of the World is expected to be $256.08 million, reflecting a 0.4% increase year over year [10]. Stock Performance - Biogen shares have decreased by 5.6% over the past month, contrasting with a 1.9% increase in the Zacks S&P 500 composite [10].

Biogen Inc. (BIIB) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February ...

Biogen (BIIB) and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the approval of Leqembi (lecanemab) for mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD, collectively known as early AD, in the EU.Please note that, in November 2024, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion recommending marketing approval for Leqembi for early AD.Biogen and Eisai annou ...

TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD) in the European Union. In November 2024, a posit ...

Biogen (BIIB) announced that the FDA has approved a monthly maintenance dosing version for its intravenously (IV) administered Alzheimer's disease (AD) drug, Leqembi.Post the FDA approval, patients have the option to transition to a monthly maintenance dosing regimen of Leqembi after completing an 18-month course of biweekly infusions of the drug. Alternatively, patients can also opt to continue with the biweekly dosing regimen.The new option provides relief to AD patients taking Leqembi, as IV administrati ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy TOKYO and CAMBRIDGE, Mass., Jan. 26, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher ...